All news

Truist lifts target to USD 260.00 for Quest Diagnostics stock

Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash

Truist Financial has raised its price target for Quest Diagnostics to $260.00 while maintaining a Hold rating. This adjustment comes ahead of Quest Diagnostics' third-quarter 2026 earnings release, scheduled for October 22, 2026. The company's stock was trading at EUR 211.45 on October 15, 2026, with a market capitalization of $26.2 billion.

Read original source

DGX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.